IL264760B2 - Regional ischemia/reperfusion injury - Google Patents

Regional ischemia/reperfusion injury

Info

Publication number
IL264760B2
IL264760B2 IL264760A IL26476019A IL264760B2 IL 264760 B2 IL264760 B2 IL 264760B2 IL 264760 A IL264760 A IL 264760A IL 26476019 A IL26476019 A IL 26476019A IL 264760 B2 IL264760 B2 IL 264760B2
Authority
IL
Israel
Prior art keywords
bag3
pharmaceutical composition
ischemia
reperfusion injury
vector
Prior art date
Application number
IL264760A
Other languages
English (en)
Hebrew (he)
Other versions
IL264760B1 (en
IL264760A (https=
Original Assignee
Univ Temple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple filed Critical Univ Temple
Publication of IL264760A publication Critical patent/IL264760A/en
Publication of IL264760B1 publication Critical patent/IL264760B1/en
Publication of IL264760B2 publication Critical patent/IL264760B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL264760A 2016-08-11 2019-02-10 Regional ischemia/reperfusion injury IL264760B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662373410P 2016-08-11 2016-08-11
PCT/US2017/046237 WO2018031738A2 (en) 2016-08-11 2017-08-10 Ischemia/reperfusion injury

Publications (3)

Publication Number Publication Date
IL264760A IL264760A (https=) 2019-03-31
IL264760B1 IL264760B1 (en) 2023-03-01
IL264760B2 true IL264760B2 (en) 2023-07-01

Family

ID=61162527

Family Applications (2)

Application Number Title Priority Date Filing Date
IL264760A IL264760B2 (en) 2016-08-11 2019-02-10 Regional ischemia/reperfusion injury
IL300767A IL300767B1 (en) 2016-08-11 2023-02-19 Regional ischemia/reperfusion injury

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL300767A IL300767B1 (en) 2016-08-11 2023-02-19 Regional ischemia/reperfusion injury

Country Status (10)

Country Link
US (2) US20190183971A1 (https=)
EP (1) EP3496726A4 (https=)
JP (1) JP7164885B2 (https=)
KR (2) KR20240130829A (https=)
CN (1) CN109937045A (https=)
AU (2) AU2017311405B2 (https=)
CA (1) CA3033633A1 (https=)
IL (2) IL264760B2 (https=)
MX (1) MX2019001729A (https=)
WO (1) WO2018031738A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110438159B (zh) * 2019-07-03 2023-02-28 广州中医药大学(广州中医药研究院) 一种引发肌原纤维肌病的基因突变小鼠模型的构建方法
CN113082048B (zh) * 2021-05-08 2022-06-10 中国人民解放军陆军军医大学第二附属医院 一种Se@BSA纳米药物的制备方法及其在急性肾损伤中的应用
CN113502260A (zh) * 2021-07-16 2021-10-15 新疆医科大学第一附属医院 一种小鼠乳鼠原代心肌细胞分离与培养方法及其应用
JP2025514489A (ja) * 2022-05-03 2025-05-02 テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイアー エデュケーション 脳におけるｂａｇ３およびタンパク質品質管理

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834248A (en) * 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress
US20030175958A1 (en) * 2002-03-15 2003-09-18 Reed John C. Methods for using bag expression as a cell differentiation agent and marker
CN102170911B (zh) 2008-08-01 2014-07-02 克里夫兰生物实验室公司 用于治疗再灌注损伤的方法
KR101436684B1 (ko) * 2012-03-09 2014-09-01 가톨릭대학교 산학협력단 저산소성 허혈 예방 또는 치료용 조성물
WO2015117010A2 (en) * 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 as a target for therapy of heart failure

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN, FANG-TING; YANG, CHUNG-MAY; YANG, CHANG-HAO., THE PROTECTIVE EFFECTS OF THE PROTEASOME INHIBITOR BORTEZOMIB (VELCADE) ON ISCHEMIA-REPERFUSION INJURY IN THE RAT RETINA, 14 May 2013 (2013-05-14) *
JIANKAI ZHANG ET AL,, OVEREXPRESSION OF BAG3 ATTENUATES HYPOXIA-INDUCED CARDIOMYOCYTE APOPTOSIS BY INDUCING AUTOPHAGY, 1 January 2016 (2016-01-01) *
YAYU MA ET AL,, PUERARIN ATTENUATES ANOXIA/REOXYGENATION INJURY THROUGH ENHANCING BCL-2 ASSOCIATED ATHANOGENE 3 EXPRESSION, A MODULATOR OF APOPTOSIS AND AUTOPHAGY, 1 January 2016 (2016-01-01) *

Also Published As

Publication number Publication date
JP2019527736A (ja) 2019-10-03
IL264760B1 (en) 2023-03-01
AU2023237152B2 (en) 2026-01-22
EP3496726A4 (en) 2020-05-06
KR20240130829A (ko) 2024-08-29
KR20190042609A (ko) 2019-04-24
US20190183971A1 (en) 2019-06-20
CN109937045A (zh) 2019-06-25
IL300767A (en) 2023-04-01
CA3033633A1 (en) 2018-02-15
MX2019001729A (es) 2019-11-12
US20230390357A1 (en) 2023-12-07
AU2023237152A1 (en) 2023-10-19
JP7164885B2 (ja) 2022-11-02
IL264760A (https=) 2019-03-31
WO2018031738A2 (en) 2018-02-15
EP3496726A2 (en) 2019-06-19
IL300767B1 (en) 2026-03-01
AU2017311405B2 (en) 2023-07-13
AU2017311405A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
AU2023237152B2 (en) Ischemia/Reperfusion injury
NO327487B1 (no) Kationisk liposom samt anvendelse derav
US20250001014A1 (en) Bag3 compositions and methods
JP7834637B2 (ja) 治療用融合タンパク質
EP2473196A2 (en) Sdf-1 delivery for treating ischemic tissue
Ding et al. Robust anticancer efficacy of a biologically synthesized tumor acidity-responsive and autophagy-inducing functional Beclin 1
JP2019527736A5 (https=)
CN112274631B (zh) 重组蛋白Semaphorin3G在防治视网膜疾病中的医药用途
US12577292B2 (en) Ferritin nanocage for multi-displaying trail trimer and cancer-targeting peptide and use thereof as anticancer agent
US11944671B2 (en) Hippo pathway deficiency reverses systolic heart failure post-infarction
JP6812004B2 (ja) 膵癌に特異的な集積性を有するペプチド及びその使用
US20130123168A1 (en) Humanin and humanin-analogues for the management of atherosclerosis
CA3244143A1 (en) Polypeptides, nucleic acid constructs and vectors and their use for treating, preventing or ameliorating diseases
EP2751126A1 (en) Use of hdl-related molecules to treat and prevent proinflammatory conditions
TW202233648A (zh) 人類粒線體分裂蛋白1之肽抑製劑及使用方法
US20090181911A1 (en) Role of gax in alzheimer neurovascular dysfunction
US20250250324A1 (en) Novel fusion protein for eliminating neurodegenerative disease-causing factor and use thereof
EP3275467A1 (en) Pharmaceutical compositions for the treatment of left ventricular hypertrophy and dysfunction associated to metabolic syndrome
JP6789573B2 (ja) グリオーマに特異的な集積性を有するペプチド及びその使用
JP6839447B2 (ja) 胆道癌に特異的な集積性を有するペプチド及びその使用
WO2022074370A1 (en) Il-33 therapy for use in the treatment, prevention or management of age-related macular degeneration (amd)
Raith et al. Elongated PEO-based nanoparticles bind the high-density lipoprotein (HDL) receptor and SARS-CoV-2 cell-entry factor, SR-BI
Gattone et al. A method to facilitate and monitor expression of
JP2015214498A (ja) ホスファチジルセリンの細胞表面への表出促進剤
HK1129392A (en) Phosphatase inhibitor protein-1 as a regulator of cardiac function